Target Organs and Levels of Evidence for TR-574
Toxicology and Carcinogenesis Studies of Pyrogallol (CASRN 87-66-1) in F344/N Rats and B6C3F1 Mice (Topical Application Studies)
Chemical (Study Title) CASRN |
Peer Review Date |
Route/Exposure Levels |
Study Laboratory |
Pyrogallol 87-66-1 |
02/08/2012 |
Topical Application R&M: 0, 5, 20, OR 75 MG/KG; 50/SEX/SPECIES/DOSE |
Battelle Columbus Laboratory |
Levels of Evidence
Male Rats: No Evidence
Type |
Organ/Tissue (Lesion) |
Non-Neoplastic Lesions |
- Skin (site of application): hyperplasia; hyperkeratosis; inflammation; sebaceous gland, hyperplasia
|
Female Rats: No Evidence
Type |
Organ/Tissue (Lesion) |
Non-Neoplastic Lesions |
- Skin (site of application): hyperplasia; hyperkeratosis; inflammation; sebaceous gland, hyperplasia
|
Male Mice: Equivocal Evidence
Type |
Organ/Tissue (Lesion) |
May Have Been Related |
- Skin: (site of application): squamous cell carcinoma 0/50, 0/50, 0/50, 2/50
|
Non-Neoplastic Lesions |
- Skin (site of application): hyperplasia; hyperkeratosis; inflammation; fibrosis; pigmentation; sebaceous gland, hyperplasia; ulcer
- Skin: hyperplasia; hyperkeratosis; ulcer; inflammation; fibrosis
|
Female Mice: Some Evidence
Type |
Organ/Tissue (Lesion) |
Neoplastic Lesions |
- Skin: (site of application): squamous cell carcinoma 0/50, 0/50, 0/50, 4/50
|
Non-Neoplastic Lesions |
- Skin (site of application): hyperplasia; hyperkeratosis; inflammation; fibrosis; pigmentation; sebaceous gland, hyperplasia; ulcer
- Skin: hyperplasia; hyperkeratosis; ulcer; inflammation; fibrosis; sebaceous gland, hyperplasia
- Mammary gland: hyperplasia
|